PERTOFRANE
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 56m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERTOFRANE is an oral small-molecule capsule approved in 1968 by Sanofi as an NDA product. The generic name and mechanism of action are not currently available in the dataset. The drug is in its lifecycle approaching loss of exclusivity.
LOE Approaching
As a legacy product approaching LOE with moderate competitive pressure (30%), the brand team is likely in a transition or maintenance phase with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and an approaching LOE lifecycle, PERTOFRANE offers limited career growth opportunities. Roles on this product are primarily focused on defending market share and managing generic transition, making it suitable for cost-containment or operational efficiency-focused career paths.
Brand ManagerField Sales Representative
Worked on PERTOFRANE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.